Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Non-Current Assets (2012 - 2026)

Kamada's (KMDA) quarterly Non-Current Assets came in at $183.6 million in Q2 2026, down 0.71% on a YoY basis from $184.9 million in Q2 2025, and little changed quarter-over-quarter from $183.8 million in Q1 2026.

Analysis

Kamada (KMDA) Non-Current Assets (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Non-Current Assets for 13 consecutive years, with $183.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets fell 0.71% year-over-year to $183.6 million; the trailing twelve-month figure through Jun 2026 stood at $737.5 million (down 1.17% YoY), and the FY2025 full-year result was $185.6 million, down 1.21% from the prior year.
  • Non-Current Assets was little changed at $183.6 million in Q2 2026 per KMDA's latest filing, from $183.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $187.9 million in Q4 2024 and bottomed at $183.4 million in Q4 2022.
  • Historically, Non-Current Assets has averaged $185.2 million across 5 years, with a median of $184.9 million in 2023.
  • The widest YoY moves for Non-Current Assets: up 427.45% in 2022, down 2.78% in 2022.
  • Over 5 years, Non-Current Assets stood at $183.4 million in 2022, then gained by 0.86% to $184.9 million in 2023, then rose by 1.6% to $187.9 million in 2024, then fell by 1.21% to $185.6 million in 2025, then decreased by 1.1% to $183.6 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $183.6 million, $183.8 million, and $185.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 564.41 Mn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn 183.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 183.59 Mn
Mar 31, 2026 183.79 Mn
Dec 31, 2025 185.64 Mn
Sep 30, 2025 184.48 Mn
Jun 30, 2025 184.90 Mn
Mar 31, 2025 186.61 Mn
Dec 31, 2024 187.91 Mn
Sep 30, 2024 186.80 Mn
Jun 30, 2024 184.61 Mn
Mar 31, 2024 185.37 Mn
Dec 31, 2023 184.95 Mn
Sep 30, 2023 183.90 Mn
Jun 30, 2023 184.71 Mn
Mar 31, 2023 185.39 Mn
Dec 31, 2022 183.37 Mn
Sep 30, 2022 184.48 Mn
Jun 30, 2022 185.53 Mn
Mar 31, 2022 186.93 Mn
Dec 31, 2021 188.62 Mn
Sep 30, 2021 37.58 Mn